Inmaculada
Jiménez Nácher
Publicacións nas que colabora con Inmaculada Jiménez Nácher (25)
2011
-
Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients
Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330
2010
-
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
Journal of Infectious Diseases, Vol. 202, Núm. 8, pp. 1185-1191
-
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C
Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649
-
Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial
HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204
-
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring
Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244
2009
-
Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients
Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401
2008
-
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir
Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785
-
Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
AIDS, Vol. 22, Núm. 18, pp. 2535-2537
-
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring
AIDS Research and Human Retroviruses, Vol. 24, Núm. 6, pp. 821-825
-
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822
2007
-
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study
AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241
-
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
AIDS, Vol. 21, Núm. 1, pp. 41-46
2006
-
Gene polymorphisms, isoenzyme activity, and emergence of resistance to efavirenz
Contagion: Reports, Cases, and Commentaries in HIV and Infectious Disease Research, Vol. 3, Núm. 1, pp. 18-22
-
Overview of the pharmacogenetics of HIV therapy
Pharmacogenomics Journal, Vol. 6, Núm. 4, pp. 234-245
-
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1
Clinical Infectious Diseases, Vol. 42, Núm. 2, pp. 291-295
2005
-
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis c virus-coinfected patients
Journal of Acquired Immune Deficiency Syndromes, Vol. 39, Núm. 4, pp. 401-405
-
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
Clinical Infectious Diseases, Vol. 40, Núm. 9, pp. 1358-1361
-
Nucleoside/nucleotide backbones for the treatment of HIV infection
Current Opinion in Investigational Drugs, Vol. 6, Núm. 8, pp. 812-822
-
Pharmacogenetics in HIV therapy
AIDS Reviews, Vol. 7, Núm. 2, pp. 103-112
-
Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity
HIV Clinical Trials, Vol. 6, Núm. 4, pp. 197-202